Preprint · OA
via OpenAlex
Adaptive responses of neuronal mitochondria to bioenergetic challenges: Roles in neuroplasticity and disease resistance
Sophia M. Raefsky, Mark P. Mattson
Free Radical Biology and Medicine · 2016 · ▲ 274 citations
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.freeradbiomed.2016.11.045
- Canonical
- link ↗
- Fetched
- 2026-10-03 MST
Cite this
APA
Raefsky, S.M., & Mattson, M.P. (2016). Adaptive responses of neuronal mitochondria to bioenergetic challenges: Roles in neuroplasticity and disease resistance. <em>Free Radical Biology and Medicine</em>. https://doi.org/10.1016/j.freeradbiomed.2016.11.045
Vancouver
Raefsky SM, Mattson MP. Adaptive responses of neuronal mitochondria to bioenergetic challenges: Roles in neuroplasticity and disease resistance. Free Radical Biology and Medicine. 2016. doi:10.1016/j.freeradbiomed.2016.11.045.
BibTeX
@unpublished{sophia2016Adapti,
title = {Adaptive responses of neuronal mitochondria to bioenergetic challenges: Roles in neuroplasticity and disease resistance},
author = {Sophia M. Raefsky and Mark P. Mattson},
journal = {Free Radical Biology and Medicine},
year = {2016},
doi = {10.1016/j.freeradbiomed.2016.11.045},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Journal of the Neurological Sciences 1997
Citation only
Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease
Trends in Neurosciences 2006
Citation only
Neurohormetic phytochemicals: low-dose toxins that induce adaptive neuronal stress responses
Nature 2016
Preprint · OA
RETRACTED ARTICLE: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance
AstraZeneca 2016
Open access · US-GOV
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
reMYND 2022
Open access · US-GOV
A Randomized, Placebo-controlled, Double-blind, Parallel-group Phase 2a Exploratory Study With Placebo run-in to Investigate PK/PD Effects, Safety, Tolerability and Pharmacokinetics of REM0046127 Oral Suspension Compared With Placebo in Subjects With Mild to Moderate Alzheimer's Disease
Neuroscience Letters 2007
Preprint · OA